甲状腺髄様がん市場 - 世界の産業規模、シェア、動向、機会、予測、治療別、エンドユーザー別、地域別、競合別、2020年～2030年

甲状腺髄様がんの世界市場は、2024年に14億5,000万米ドルと評価され、2030年までのCAGRは8.45%で、予測期間中に目覚ましい成長を予測しています。

甲状腺髄様がん（MTC）は、甲状腺の濾胞傍細胞（C細胞）から発生するまれではありますが臨床的に重要な甲状腺がんです。甲状腺がん全体の約1％から2％を占めます。世界の甲状腺髄様がん市場は、この複雑で課題も多い疾患の診断、管理、研究に関連する様々な製品、サービス、治療を包括しています。

世界の甲状腺髄様がん市場は、主に罹患率の上昇、診断技術の進歩、治療方法の進化、認知度の向上などの要因によって、着実な成長を遂げています。がん市場全体に占める割合は小さいものの、そのユニークな特徴と効果的な治療に対する切迫したニーズから、研究開発が活発に行われている分野です。

主要な市場促進要因

甲状腺がんの有病率の上昇

主要な市場課題

高い治療費

主要な市場動向

精密医療の進歩

目次

第1章 製品概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 甲状腺髄様がん市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 治療別（手術、放射線療法、化学療法）
  • エンドユーザー別（病院、放射線治療センター、がん研究機関）
  • 地域別
  • 企業別（2024年）
• 市場マップ

第6章 北米の甲状腺髄様がん市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の甲状腺髄様がん市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第8章 アジア太平洋の甲状腺髄様がん市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米の甲状腺髄様がん市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの甲状腺髄様がん市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 世界の甲状腺髄様がん市場：SWOT分析

第14章 競合情勢

• AstraZeneca PLC
• Sanofi AG
• Eli Lilly and Company
• Exelixis, Inc.
• F. Hoffmann-La Roche Ltd
• Novartis AG
• Merck & Co., Inc
• Bayer AG
• HUTCHMED Ltd.
• Bristol-Myers Squibb Co.

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Medullary Thyroid Cancer Market was valued at USD 1.45 Billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 8.45% through 2030. Medullary Thyroid Cancer (MTC) is a rare but clinically significant form of thyroid cancer that arises from the parafollicular cells (C cells) of the thyroid gland. It accounts for approximately 1-2% of all thyroid cancers. The Global Medullary Thyroid Cancer Market encompasses the various products, services, and treatments associated with the diagnosis, management, and research of this complex and challenging disease.

The Global Medullary Thyroid Cancer Market is witnessing steady growth, primarily driven by factors such as rising incidence rates, advancements in diagnostic technologies, evolving treatment modalities, and increasing awareness. While it represents a small segment of the overall cancer market, its unique characteristics and the pressing need for effective treatments make it an area of active research and development.

Key Market Drivers

Rising Prevalence of Thyroid Cancer

The rising prevalence of thyroid cancer is a significant driver of growth in the Global Medullary Thyroid Cancer (MTC) Market. In 2020, approximately 586,000 cases of thyroid cancer were recorded globally, positioning it as the 10th most prevalent cancer worldwide. The disease exhibited a significant gender disparity, with an estimated 449,000 cases in females compared to 137,000 cases in males, highlighting that thyroid cancer occurs at three times the rate in women relative to men. As more cases of thyroid cancer, including MTC, are diagnosed worldwide, the demand for diagnostic solutions, advanced treatments, and targeted therapies continues to rise. This increasing prevalence influences multiple market factors, from pharmaceutical innovation to healthcare infrastructure development, ultimately fueling market expansion. The growing incidence of thyroid cancer directly contributes to the demand for effective therapies, especially for rare subtypes like MTC. Medullary thyroid cancer (MTC) is a rare neuroendocrine malignancy, representing 1% to 5% of all diagnosed thyroid cancer cases, its unique clinical characteristics and aggressive nature necessitate specialized treatment approaches. Global thyroid cancer incidence has been steadily rising over the past two decades, partly due to improved screening programs. Studies show a higher detection rate of MTC cases, particularly in high-income countries with advanced healthcare infrastructure. As more patients are diagnosed with MTC, the market size for MTC-specific treatments expands. This encourages pharmaceutical companies to invest in drug development and clinical trials to meet the growing demand.

Key Market Challenges

High Treatment Costs

The cost of treating medullary thyroid cancer, particularly with advanced therapies and targeted medications, can be exorbitant. These high treatment costs pose a substantial challenge for patients, healthcare systems, and insurers. Patients may face financial strain, while healthcare providers may struggle to offer the latest treatments due to budget constraints. Additionally, insurers may impose restrictions on coverage for certain treatments.

Limited access to cutting-edge therapies for patients without adequate insurance coverage. Healthcare providers may need to make difficult decisions regarding resource allocation. Financial burden on patients may lead to treatment non-compliance and adverse outcomes.

Key Market Trends

Advancements in Precision Medicine

Precision medicine is revolutionizing the approach to treating medullary thyroid cancer. This trend involves tailoring treatments to individual patients based on their specific genetic mutations and disease characteristics. As our understanding of the genetic underpinnings of medullary thyroid cancer deepens, more targeted therapies are being developed. These therapies aim to inhibit the specific molecular pathways driving cancer growth, resulting in more effective and less toxic treatments.

Key Market Players

• AstraZeneca PLC
• Sanofi AG
• Eli Lilly and Company
• Exelixis, Inc.
• F. Hoffmann-La Roche Ltd
• Novartis AG
• Merck & Co., Inc
• Bayer AG
• HUTCHMED Ltd.
• Bristol-Myers Squibb Co.

Report Scope:

In this report, the Global Medullary Thyroid Cancer Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Medullary Thyroid Cancer Market, By Treatment:

• Surgery
• Radiation Therapy
• Chemotherapy

Medullary Thyroid Cancer Market, By End-User:

• Hospitals
• Radiation Therapy Center
• Cancer Research Institutes

Medullary Thyroid Cancer Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Medullary Thyroid Cancer Market.

Available Customizations:

Global Medullary Thyroid Cancer market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Medullary Thyroid Cancer Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment (Surgery, Radiation Therapy, Chemotherapy)
  • 5.2.2. By End-User (Hospitals, Radiation Therapy Center, Cancer Research Institutes)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Medullary Thyroid Cancer Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment
  • 6.2.2. By End User
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Medullary Thyroid Cancer Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment
      • 6.3.1.2.2. By End User
  • 6.3.2. Canada Medullary Thyroid Cancer Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment
      • 6.3.2.2.2. By End User
  • 6.3.3. Mexico Medullary Thyroid Cancer Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment
      • 6.3.3.2.2. By End User

7. Europe Medullary Thyroid Cancer Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment
  • 7.2.2. By End User
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Medullary Thyroid Cancer Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment
      • 7.3.1.2.2. By End User
  • 7.3.2. United Kingdom Medullary Thyroid Cancer Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment
      • 7.3.2.2.2. By End User
  • 7.3.3. Italy Medullary Thyroid Cancer Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment
      • 7.3.3.2.2. By End User
  • 7.3.4. France Medullary Thyroid Cancer Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Treatment
      • 7.3.4.2.2. By End User
  • 7.3.5. Spain Medullary Thyroid Cancer Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Treatment
      • 7.3.5.2.2. By End User

8. Asia-Pacific Medullary Thyroid Cancer Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment
  • 8.2.2. By End User
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Medullary Thyroid Cancer Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment
      • 8.3.1.2.2. By End User
  • 8.3.2. India Medullary Thyroid Cancer Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment
      • 8.3.2.2.2. By End User
  • 8.3.3. Japan Medullary Thyroid Cancer Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment
      • 8.3.3.2.2. By End User
  • 8.3.4. South Korea Medullary Thyroid Cancer Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Treatment
      • 8.3.4.2.2. By End User
  • 8.3.5. Australia Medullary Thyroid Cancer Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Treatment
      • 8.3.5.2.2. By End User

9. South America Medullary Thyroid Cancer Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment
  • 9.2.2. By End User
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Medullary Thyroid Cancer Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment
      • 9.3.1.2.2. By End User
  • 9.3.2. Argentina Medullary Thyroid Cancer Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment
      • 9.3.2.2.2. By End User
  • 9.3.3. Colombia Medullary Thyroid Cancer Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment
      • 9.3.3.2.2. By End User

10. Middle East and Africa Medullary Thyroid Cancer Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Treatment
  • 10.2.2. By End User
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Medullary Thyroid Cancer Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Treatment
      • 10.3.1.2.2. By End User
  • 10.3.2. Saudi Arabia Medullary Thyroid Cancer Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Treatment
      • 10.3.2.2.2. By End User
  • 10.3.3. UAE Medullary Thyroid Cancer Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Treatment
      • 10.3.3.2.2. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Medullary Thyroid Cancer Market: SWOT Analysis

14. Competitive Landscape

• 14.1. AstraZeneca PLC
  • 14.1.1. Business Overview
  • 14.1.2. Product & Service Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (If Listed)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. Sanofi AG
• 14.3. Eli Lilly and Company
• 14.4. Exelixis, Inc.
• 14.5. F. Hoffmann-La Roche Ltd
• 14.6. Novartis AG
• 14.7. Merck & Co., Inc
• 14.8. Bayer AG
• 14.9. HUTCHMED Ltd.
• 14.10.Bristol-Myers Squibb Co.

15. Strategic Recommendations

16. About Us & Disclaimer